RESTRICTED AREA
* The information contained on this page is intended for veterinarians or animal health professionals with the ability to prescribe and/or dispense medicines.If you meet these requirements, talk to our sales department.
Ref.: VT 47 860
PROTEQFLU-TE 10X1DS
Influenza + Tétanos
If you have already registered, log in to GirovetPro
Description
PHARMACEUTICAL FORM
Injectable suspension.
SPECIES
Horses.
Injectable suspension.
SPECIES
Horses.
Indications
Active immunization of horses 4 months of age or older against equine influenza by reducing the clinical signs and viral excretion after the infection and against tetanus to prevent mortality.
- Start of immunity: 14 days after the primary vaccination.
- Duration of immunity induced by vaccination schedule:
- Start of immunity: 14 days after the primary vaccination.
- Duration of immunity induced by vaccination schedule:
- 5 months after the primary vaccination.
- After the primary vaccination and the booster injection 5 months later, 1 year for equine influenza and 2 years for tetanus.
Dose / Application / Administration
Route of administration:
Intramuscular.
Dosage:
Administer one dose (1ml) by intramuscular injection, preferably in the neck, according to the following vaccination schedule:
Intramuscular.
Dosage:
Administer one dose (1ml) by intramuscular injection, preferably in the neck, according to the following vaccination schedule:
- Primary vaccination with ProteqFlu-Te: first injection from 5 – 6 months, second injection 4 – 6 weeks later.
- Booster injection: 5 months after the primary vaccination with ProteqFlu-Te. Followed by or against tetanus: injection of 1 dose with a maximum interval of 2 years with ProteqFlu-Te. / Or against equine influenza: injection of 1 dose every year, alternatively with ProteqFlu. / Or ProteqFlu-Te, respecting an interval of 2 years for the tetanus component.
It can be used during pregnancy and lactation.
Composition
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1ml contains:
Active substances:
Recombinant canaripox virus Influenza A/eq/Ohio/03 [H3N8] (vCP2242): ≥ 5,3 log10 DIIF50*
Recombinant canaripox virus Influenza A/eq/Richmond/1/07 [H3N8] (vCP3011): ≥ 5,3 log10 DIIF50*
*vCP content checked by DIIF50 global (infectious dose 50 % by immunofluorescence) and qPCR ratio between vCP.
Adjuvant:
Carbomer: 4mg
Each dose of 1ml contains:
Active substances:
Recombinant canaripox virus Influenza A/eq/Ohio/03 [H3N8] (vCP2242): ≥ 5,3 log10 DIIF50*
Recombinant canaripox virus Influenza A/eq/Richmond/1/07 [H3N8] (vCP3011): ≥ 5,3 log10 DIIF50*
*vCP content checked by DIIF50 global (infectious dose 50 % by immunofluorescence) and qPCR ratio between vCP.
Adjuvant:
Carbomer: 4mg
Presentation
10 vials of 1ml
Laboratory
BOEHRINGER
Leave us your comment